ArticleJournal of menopausal medicine2025
Impact of Hormone Therapy on Ocular Disease Risk in Postmenopausal Women: Evidence from the Korean National Health Insurance Service Database.
Article in Journal of menopausal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing Healthspan in Women: A New Paradigm for Successful Aging through the Menopausal Transition.Journal of menopausal medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesThis study aimed to evaluate the relationship between menopausal hormone therapy (MHT) and the development of major ocular diseases, including cataract, glaucoma, and retinal disorders.
methodsThis retrospective cohort study used data from the Korean National Health Insurance Service database (2005-2015) comprising 23,333 women diagnosed with menopause, International Classification of Diseases, 10th Revision code N95. Participants were categorized into MHT and non-MHT groups. Incidence rate ratios (IRRs) of ophthalmologic diseases were analyzed, with subgroup analyses by age at menopause, time to MHT initiation, and duration of therapy.
resultsA total of 18,228 women were included. The MHT group had a significantly lower incidence of glaucoma than the non-MHT group (IRR 0.921, 95% confidence interval [CI] [0.869, 0.975]). The protective effect was most evident in women who experienced menopause at 40-49 years (IRR 0.851, 95% CI [0.762, 0.951]). Initiating MHT within 1 year of menopause was linked to a reduced glaucoma risk (IRR 0.896, 95% CI [0.844, 0.951]), while delayed initiation increased the risk (IRR 1.161, 95% CI [1.024, 1.316]). MHT use for ≥ 365 days was associated with lower risks of glaucoma (IRR 0.888, 95% CI [0.816, 0.967]) and retinal disorders (IRR 0.886, 95% CI [0.789, 0.995]) compared to shorter use.
conclusionsMHT use is associated with reduced glaucoma risk in postmenopausal women, especially those aged 40-49 years. These findings highlight the potential ocular benefits of MHT and the importance of early initiation in younger menopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.